The antibody–drug conjugate brentuximab vedotin (BV) combines a CD30 monoclonal antibody with the antimitotic agent monomethyl auristatin E. Phase I/II studies suggested clinical utility in TCL, with the most pronounced benefits observed in patients with CTCL and systemic ALCL (sALCL) in these early trials [237,238,239]. The gene discussed is TNFRSF8; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.